Bitcoin groundbreakers share personal stories of how Bitcoin is changing lives for the better. Host Mauricio Di Bartolomeo, co-founder and CSO of Ledn, speaks with leading Bitcoin voices, entrepreneurs, and human rights advocates to hear their unique journey and practical real-world examples of how Bitcoin has made a positive impact in their lives. Brought to you by Ledn, a leading financial services company built for Bitcoin & digital assets. Ledn offers a suite of lending, saving and tradi ...
…
continue reading
المحتوى المقدم من Proactive Investors. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Proactive Investors أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Player FM - تطبيق بودكاست
انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
Theralase Explores Synergistic Drug Combinations for Cancer Treatment
MP3•منزل الحلقة
Manage episode 436671949 series 2891889
المحتوى المقدم من Proactive Investors. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Proactive Investors أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Theralase Technologies CEO Roger DuMoulin-White joined Steve Darling from Proactive to announce a significant advancement in cancer treatment. The company's lead drug formulation, Rutherrin, has demonstrated a remarkable ability to enhance the efficacy of Cisplatin, a commonly prescribed chemotherapy drug, in treating chemotherapy-resistant Non-Small Cell Lung Cancer in a preclinical animal model. DuMoulin-White detailed the experimentation process, where mice were divided into two groups: a control group treated with Cisplatin alone and an active group treated with a combination of Cisplatin and Rutherrin. The results were striking. The mice in the active group showed a significantly higher enhancement of Cisplatin efficacy, marked by a notable increase in overall survival compared to the control group. The statistical significance of these results highlights the potential impact of Rutherrin in improving treatment outcomes for patients with aggressive NSCLC. Theralase Technologies believes that the efficacy of Rutherrin could be further improved by combining it with additional treatments such as radiation or Metformin, which could activate Rutherrin® while it resides in NSCLC cells. This promising preclinical data lays the groundwork for future studies and potential clinical applications, offering new hope for patients battling resistant forms of lung cancer. #proactiveinvestors #theralasetechnologiesinc #tsxv #tlt #otcqb #tftff #MedicalResearch #HealthcareInnovation #PatientCare #CancerResearch #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
611 حلقات
MP3•منزل الحلقة
Manage episode 436671949 series 2891889
المحتوى المقدم من Proactive Investors. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Proactive Investors أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Theralase Technologies CEO Roger DuMoulin-White joined Steve Darling from Proactive to announce a significant advancement in cancer treatment. The company's lead drug formulation, Rutherrin, has demonstrated a remarkable ability to enhance the efficacy of Cisplatin, a commonly prescribed chemotherapy drug, in treating chemotherapy-resistant Non-Small Cell Lung Cancer in a preclinical animal model. DuMoulin-White detailed the experimentation process, where mice were divided into two groups: a control group treated with Cisplatin alone and an active group treated with a combination of Cisplatin and Rutherrin. The results were striking. The mice in the active group showed a significantly higher enhancement of Cisplatin efficacy, marked by a notable increase in overall survival compared to the control group. The statistical significance of these results highlights the potential impact of Rutherrin in improving treatment outcomes for patients with aggressive NSCLC. Theralase Technologies believes that the efficacy of Rutherrin could be further improved by combining it with additional treatments such as radiation or Metformin, which could activate Rutherrin® while it resides in NSCLC cells. This promising preclinical data lays the groundwork for future studies and potential clinical applications, offering new hope for patients battling resistant forms of lung cancer. #proactiveinvestors #theralasetechnologiesinc #tsxv #tlt #otcqb #tftff #MedicalResearch #HealthcareInnovation #PatientCare #CancerResearch #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
611 حلقات
Semua episod
×مرحبًا بك في مشغل أف ام!
يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.